Source: DGNews  |  Posted 8 years ago

By Alison Palkhivala

BANFF, AB -- August 8, 2003 -- Pegylated liposomal doxorubicin (PLD, Doxil) has important properties that differentiate it from both free doxorubicin and liposomal doxorubicin, making it just as effective a therapy but with a reduced toxicity profile.

Stephen R. D. Johnston, MD, PhD, consultant in medical oncology, Royal Marsden Hospital, London, United Kingdom, spoke about the clinical utility of PLD in breast cancer here August 1st at the Second Annual Future of Breast Cancer: An International Breast Cancer Congress.

Liposomes are lipid bilayer spheres into which doxorubicin is concentrated, Dr. Johnston explained. PLD differs from regular liposomal doxorubicin in 2 important ways. "The differences with pegylated liposomal doxorubicin